Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2023-06-01 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated June 1, 2023, addressed to stock exchanges, informing about the schedule of an Analyst/Institutional Investor Meeting. It references regulatory compliance (SEBI Listing Obligations) and provides a meeting date and type. The content is an announcement of a meeting schedule rather than a detailed financial report, presentation, or transcript. The document length is only 1520 characters, indicating it is brief and informational. This fits the category of an Investor Presentation announcement or meeting schedule notice. However, since it is only a schedule/intimation of a meeting and not the presentation itself or transcript, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories like IP or CT. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying the schedule of analyst and institutional investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which governs disclosures related to investor relations activities. The content is about scheduling meetings with investors and analysts, which is typical of an Investor Presentation or related communication. However, the document itself is not a presentation or detailed financial report but an announcement of upcoming meetings with investors. Given the short length (1592 characters) and the nature of the content (schedule notification), it does not qualify as a full Investor Presentation (IP) or a financial report. It is best classified as a Regulatory Filing (RNS) because it is a regulatory disclosure about investor meetings without substantive financial data or presentation content.
2023-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled 'Earnings call Transcript- Q4FY23' and includes detailed text of a conference call held on May 18, 2023, discussing the company's financial results for the fourth quarter and full fiscal year 2023. It contains management commentary, financial performance data, and Q&A session details. The presence of a full transcript of the earnings call, including management remarks and financial figures, clearly identifies this as a Call Transcript (CT). The document length is substantial (15,000 characters), and it is not merely an announcement or summary but the full transcript itself.
2023-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated May 25, 2023, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which pertains to disclosure of material events. The content is an announcement of a meeting schedule, not a detailed financial report or presentation. The document length is only 1557 characters, indicating it is a brief announcement rather than a full investor presentation or report. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor meetings, but since it only announces the schedule and does not contain detailed presentation content, it is more appropriate to classify it as a Regulatory Filing (RNS) which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-05-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated May 24, 2023, addressed to stock exchanges, informing about the schedule of analyst and institutional investor meetings. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which governs disclosures related to investor relations. The content is purely an announcement of upcoming investor meetings and does not contain any financial data, report, or detailed presentation. The document length is only 1590 characters, indicating it is a brief notice rather than a full report or transcript. Therefore, it fits best under the category of Investor Presentation (IP) as it relates to investor meetings and presentations, but since it only announces the schedule and does not contain the presentation itself, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Hence, the classification is Regulatory Filings (RNS) with high confidence.
2023-05-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a short notice dated May 23, 2023, addressed to stock exchanges regarding the schedule of an Analyst/Institutional Investor Meeting. It references compliance with SEBI regulations and provides details of a one-on-one meeting with an investor. The document is only 1500 characters long and does not contain any financial data, results, or detailed presentations. It is an announcement about an upcoming investor meeting rather than the meeting materials or transcript itself. Therefore, it fits the category of Investor Presentation announcements or meeting schedule notifications. Given the definitions, the best fit is Investor Presentation (IP) as it relates to investor meetings and presentations, even though it is a schedule notice rather than the presentation itself. However, since it is only a schedule notice and not the presentation content, it is closest to an Investor Presentation announcement rather than a full report. Confidence is high due to clear regulatory references and meeting details.
2023-05-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.